|

Teclistamab Clinical Trials

23 actively recruiting trials across 13 locations

▼ -2 trials since July 2026

Also known as: (TECVAYLI™), Daratumumab, JNJ 64007957, JNJ-64007957, JNJ64007957 +6 more

Pipeline

Phase 1: 4Phase 2: 10Phase 3: 5Phase 4: 1Phase 1/2: 1

Top Sponsors

Janssen Research & Development, LLC3
National Cancer Institute (NCI)2
European Myeloma Network B.V.2
University of Leeds1
University Hospital, Lille1

Indications

Cancer23
Multiple Myeloma16
Recurrent Multiple Myeloma2
Multiple Myeloma (MM)2
Refractory Multiple Myeloma2

Other8 trials

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Phase 2

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Phase 2

Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

Phase 3

Plan Development for Giving Teclistamab in the Outpatient Setting

Phase 4

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Phase 2

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Phase 2

Study on the Clinical Efficacy of Teclistamab

The Norwegian Immunotherapy in Multiple Myeloma Study

Phoenix, Arizona3 trials

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Mayo Clinic Phoenix

Phase 3

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Banner University Medical Center Tucson, University of Arizona

Phase 3

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Mayo Clinic Hospital in Arizona

Phase 1

Birmingham, Alabama1 trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Alabama Oncology

Phase 3

Gilbert, Arizona1 trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3

Tucson, Arizona1 trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Arizona Oncology Associates

Phase 2

Duarte, California1 trial

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

City of Hope Comprehensive Cancer Center LAO

Phase 1

Denver, Colorado1 trial

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Colorado Blood Cancer Institute

Phase 2

New Haven, Connecticut1 trial

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Yale University

Phase 2

Miami, Florida1 trial

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

University of Miami

Phase 2

Atlanta, Georgia1 trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

Iowa City, Iowa1 trial

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

University of Iowa Health Care

Phase 1

Boston, Massachusetts1 trial

Teclistamab-Daratumumab in AL Amyloidosis

Boston Medical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Columbus, Ohio1 trial

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.